{
  "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0",
  "docSlug": "2296286e07283457e97b21dc9ce59469",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 46,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide compares two disease indications side-by-side with clinical metrics and competitive market context.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/16",
  "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0",
  "deckJsonHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0.json",
  "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.96,
        "x": 0.02,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "Source: BMS First Quarter 2022 financial results; 'Genmab Improves Its 2022 Financial Guidance' November 3 2022, Celgene Second Quarter 2019 Operating and Financial Results...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "44f35c69-6371-409e-92ba-00150883103f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.53,
        "y": 0.22
      },
      "kind": "list",
      "text": "100% Overall Response + 75% Organ Response (Cardiac, renal, liver) in Relapsed/Refractory Amyloidosis Patients; Duration of Response Not Yet Reached at a median follow-up of 5.2 months; 2-stage improvement in NYHA stage was observed with NXC-201; Mean 65% reduction (2,656pg/mL) in NT-proBNP from baseline; Outpatient CAR-T Potential; Published in Clinical Cancer Research 2022 + 5th European CAR-T Cell Meeting + 49th EBMT meeting + 29th ASCGT 2023 (Los Angeles); Data in 8 patients so far",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1190cf3-044c-49aa-881f-45945177ca5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "list",
      "text": "92% Overall Response Rate in Heavily Pretreated Multiple Myeloma Patients 60% CR/sCR (sCR 10^-5) rate; No Neurotoxicity observed; 1 Grade 3, No Grade 4 Cytokine Release Syndrome (CRS) Observed at planned RP2D 800 million CAR+T cells; Outpatient CAR-T Potential; Published in Haematologica 2022 + 5th European CAR-T Cell Meeting + EBMT 49th Annual meeting; Data in 50 patients so far",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4520fd5-f4c5-4a2c-bccc-762dad5caa00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.53,
        "y": 0.85
      },
      "kind": "table",
      "text": "14,982 patient annual incidence",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5c84774-7faa-463f-90c6-67f77d2dce72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.85
      },
      "kind": "table",
      "text": "176,404 patient annual incidence",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0f18f7a-ba5e-4acb-b54e-413e9ef66e92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "NXC-201 Clinical Highlights: No Neurotoxicity Across 42 Patients; Outpatient CAR-T Potential",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0946b4e-faf2-4352-88fa-5f42d5fe5aaf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 10,
      "beatId": "ec348a34-4a83-4f17-b0f0-268fe2d31e3a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation presents Immix Biopharma's solutions and clinical results.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "d3ed2b4b-7476-486a-bc9e-587ba67669a2",
      "evidence": "The presentation presents clinical results and data to support the solutions.",
      "position": 1,
      "objective": "What are the potential benefits of Immix Biopharma's solutions?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}